The aim of this study was to prospectively evaluate the potential of the dual ET-1 receptor antagonist (ETA and ETB receptor) macitentan to mitigate alveolar and cardiovascular remodelling using the established in-vivo hyperoxia BPD infant rat model [23–25]. This evidence concerns the gene EDNRA and bronchopulmonary dysplasia.